102 related articles for article (PubMed ID: 12493819)
1. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones.
Lister PD
J Antimicrob Chemother; 2003 Jan; 51(1):199-202. PubMed ID: 12493819
[No Abstract] [Full Text] [Related]
2. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.
Nicolau DP; Mattoes HM; Banevicius M; Xuan D; Nightingale CH
Antimicrob Agents Chemother; 2003 May; 47(5):1630-5. PubMed ID: 12709332
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of BMS 284756, a novel des-fluoro (6) quinolone and seven fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Pawlak J; Belian B
Clin Microbiol Infect; 2001 Oct; 7(10):572-3. PubMed ID: 11683802
[No Abstract] [Full Text] [Related]
4. Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
Anderegg TR; Biedenbach DJ; Jones RN;
Diagn Microbiol Infect Dis; 2003 Jun; 46(2):147-50. PubMed ID: 12812719
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Hammerschlag MR
Int J Antimicrob Agents; 2003 Jun; 21(6):578-80. PubMed ID: 12791473
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones.
Schmitz FJ; Boos M; Mayer S; Köhrer K; Scheuring S; Fluit AC
Antimicrob Agents Chemother; 2002 Mar; 46(3):934-5. PubMed ID: 11850293
[No Abstract] [Full Text] [Related]
7. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
Gales A; Sader H; Jones RN;
Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
[TBL] [Abstract][Full Text] [Related]
8. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
Weller TM; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.
Morosini MI; Loza E; del Campo R; Almaraz F; Baquero F; Cantón R
Antimicrob Agents Chemother; 2003 Aug; 47(8):2692-5. PubMed ID: 12878544
[TBL] [Abstract][Full Text] [Related]
10. Antipneumococcal activity of BMS 284756 compared to those of six other agents.
Pankuch GA; Nagai K; Davies TA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2002 Jan; 46(1):251-4. PubMed ID: 11751147
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.
Lister PD
Antimicrob Agents Chemother; 2002 Jan; 46(1):69-74. PubMed ID: 11751113
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae.
Boswell FJ; Andrews JM; Wise R
J Antimicrob Chemother; 2001 Sep; 48(3):446-7. PubMed ID: 11533016
[No Abstract] [Full Text] [Related]
13. Induction of in vitro resistance to BMS-284756 by Streptococcus pneumoniae.
Schmitz FJ; Boos M; Jagusch H; Mayer S; Fluit AC; Hafner D
J Antimicrob Chemother; 2001 Oct; 48(4):588-90. PubMed ID: 11581245
[No Abstract] [Full Text] [Related]
14. In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility.
Schmitz FJ; Milatovic D; Boos M; Mayer S; Fluit AC
J Antimicrob Chemother; 2002 Apr; 49(4):698-701. PubMed ID: 11909849
[No Abstract] [Full Text] [Related]
15. Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.
Gordon KA; Rhomberg PR; Jones RN
J Clin Microbiol; 2003 Aug; 41(8):3967-9. PubMed ID: 12904431
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756).
Hayashi K; Takahata M; Kawamura Y; Todo Y
Arzneimittelforschung; 2002; 52(12):903-13. PubMed ID: 12572531
[TBL] [Abstract][Full Text] [Related]
17. Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus.
Schmitz FJ; Boos M; Mayer S; Jagusch H; Fluit AC
J Antimicrob Chemother; 2002 Feb; 49(2):283-7. PubMed ID: 11815569
[TBL] [Abstract][Full Text] [Related]
18. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
Hecht DW; Osmolski JR
Antimicrob Agents Chemother; 2003 Mar; 47(3):910-6. PubMed ID: 12604521
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
[TBL] [Abstract][Full Text] [Related]
20. Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2003 Mar; 47(3):1140-2. PubMed ID: 12604557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
